Clinical Characteristics and Disease Progression in Early-Stage COVID-19 Patients in South Korea
Clinical Characteristics and Disease Progression in Early-Stage COVID-19 Patients in South Korea
复制标题
DOI：
10.3390/jcm9061959
复制
发表时间：
2020-06-01
影响因子：
3.9
通讯作者：
Jeong, Seok Hoon
中科院分区：
文献类型：
--
作者：
Choi, Min Hyuk;Ahn, Hyunmin;Jeong, Seok Hoon
冠状病毒病 19 (COVID-19) 患者数量的快速增加可能会超出现有的医疗资源。我们的目的是评估 COVID-19 早期阶段疾病严重程度的危险因素。该队列由 2020 年 3 月 5 日至 2020 年 3 月 18 日期间的 293 名 COVID-19 患者组成。韩国疾病控制和预防中心 (KCDC) 分类系统用于对患者进行分类。总结了临床过程，包括药物（血管紧张素II受体阻滞剂[ARB]、布洛芬和二肽基肽酶4抑制剂[DPP4i]）的影响以及洛匹那韦/利托那韦的治疗效果。调整混杂变量后，既往药物使用史（包括 ARB、布洛芬和 DPP4i）并不是与疾病进展相关的危险因素。接受洛匹那韦/利托那韦治疗的患者的无进展生存期明显短于未接受洛匹那韦/利托那韦治疗的患者。 KCDC 分类 I 清楚地区分了 COVID-19 患者的改善/稳定组和进展组（AUC 0.817；95% CI，0.740-0.895）。
A rapid increase in the number of patients with coronavirus disease 19 (COVID-19) may overwhelm the available medical resources. We aimed to evaluate risk factors for disease severity in the early stages of COVID-19. The cohort comprised 293 patients with COVID-19 from 5 March 2020, to 18 March 2020. The Korea Centers for Disease Control and Prevention (KCDC) classification system was used to triage patients. The clinical course was summarized, including the impact of drugs (angiotensin II receptor blockers [ARB], ibuprofen, and dipeptidyl peptidase-4 inhibitors [DPP4i]) and the therapeutic effect of lopinavir/ritonavir. After adjusting for confounding variables, prior history of drug use, including ARB, ibuprofen, and DPP4i was not a risk factor associated with disease progression. Patients treated with lopinavir/ritonavir had significantly shorter progression-free survival than those not receiving lopinavir/ritonavir. KCDC classification I clearly distinguished the improvement/stabilization group from the progression group of COVID-19 patients (AUC 0.817; 95% CI, 0.740-0.895).